SCHEMBL20148012

SCHEMBL20148012

Cc1cc(C(=O)NC2(C)CCN(C(C)S)CC2)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.41
CNR2 P34972 1/20 0.39
ACKR3 P25106 2/20 0.38
MCHR1 Q99705 1/20 0.36
PROKR1 Q8TCW9 1/20 0.35
ABL1 P00519 1/20 0.35
WNT1 P04628 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
WDR5 P61964 1/20 0.35
SLC6A3 Q01959 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
KMT2A Q03164 1/20 0.34
NTRK1 P04629 1/20 0.34
ROCK2 O75116 1/20 0.34
NAMPT P43490 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147637 0.91 RET (0.41) RETCNR2ACKR3MCHR1PROKR1
SCHEMBL25504179 0.85 RET (0.42) RETCNR2ACKR3MCHR1PROKR1
SCHEMBL20070352 0.84 RET (0.43) RETCNR2ACKR3MCHR1PROKR1
SCHEMBL20205976 0.81 RET (0.40) RETCNR2MCHR1KMT2A
SCHEMBL20158552 0.77 RET (0.42) RET
SCHEMBL20158753 0.77 RET (0.37) RETCNR2
SCHEMBL25504248 0.77 RET (0.40) RETNTRK1
SCHEMBL20158859 0.77 MCHR1 (0.39) RETCNR2MCHR1GSK3BWDR5
SCHEMBL20158441 0.77 BDKRB1 (0.39) CNR2MCHR1
SCHEMBL20147622 0.75 MCHR1 (0.42) RETCNR2MCHR1ABL1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885CNR2 4423/4885ACKR3 1015/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885CNR2 4423/4885ACKR3 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.